AGIOS PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $29.98 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $29.20, a 12.00% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $33.18, a 3.04% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $32.20, a 25.44% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $25.67, a 20.35% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $33.75, a 1.89% decline from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $34.40, a 33.13% increase from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $25.84, a 10.56% decline from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $28.89, a 47.98% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.98 10-Q · filed 2026-07-30 | |||
| 2026-03-31 | $29.20 10-Q · filed 2026-04-29 | |||
| 2025-12-31 | $33.75 10-K · filed 2026-02-12 | |||
| 2025-09-30 | $33.59 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | $33.40 10-Q · filed 2025-07-31 | |||
| 2025-03-31 | $33.18 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | $34.40 10-K · filed 2025-02-13 | |||
| 2024-09-30 | $34.04 10-Q · filed 2024-10-31 | |||
| 2024-06-30 | $33.39 10-Q · filed 2024-08-01 | |||
| 2024-03-31 | $32.20 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $25.84 10-K · filed 2024-02-15 | |||
| 2023-09-30 | $25.88 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $25.84 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $25.67 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $28.89 10-K · filed 2023-02-23 | |||
| 2022-09-30 | $28.89 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $29.08 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $32.23 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $55.54 10-K · filed 2022-02-24 | |||
| 2021-09-30 | $55.95 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | $56.17 10-Q · filed 2021-07-29 | |||
| 2021-03-31 | $56.17 10-Q · filed 2021-04-29 | |||
| 2020-12-31 | $49.42 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $49.84 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $50.09 10-Q · filed 2020-07-30 | |||
| 2020-03-31 | $51.09 10-Q · filed 2020-04-30 | |||
| 2019-12-31 | $53.79 10-K · filed 2020-02-19 | |||
| 2019-09-30 | $55.85 10-Q · filed 2019-10-31 | |||
| 2019-06-30 | $57.08 10-Q · filed 2019-08-01 | |||
| 2019-03-31 | $57.47 10-Q · filed 2019-05-02 | |||
| 2018-12-31 | $78.10 10-K · filed 2019-02-14 | |||
| 2018-09-30 | $78.35 10-Q · filed 2018-11-01 | |||
| 2018-06-30 | $78.14 10-Q · filed 2018-08-02 | |||
| 2018-03-31 | $77.22 10-Q · filed 2018-05-04 | |||
| 2017-12-31 | $51.78 10-K · filed 2018-02-14 | |||
| 2017-09-30 | $50.61 10-Q · filed 2017-11-01 | |||
| 2017-06-30 | $50.12 10-Q · filed 2017-08-08 | |||
| 2017-03-31 | $49.85 10-Q · filed 2017-05-04 | |||
| 2016-12-31 | $43.99 10-K · filed 2017-02-16 | |||
| 2016-09-30 | $43.18 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $42.61 10-Q · filed 2016-08-08 | |||
| 2016-03-31 | $40.87 10-Q · filed 2016-05-09 | |||
| 2015-12-31 | $104.14 10-K · filed 2016-02-26 | |||
| 2015-09-30 | $107.11 10-Q · filed 2015-11-06 | |||
| 2015-06-30 | $107.27 10-Q · filed 2015-08-07 | |||
| 2015-03-31 | $108.21 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $39.49 10-K · filed 2015-02-24 | |||
| 2014-09-30 | $33.23 10-Q · filed 2014-11-07 | |||
| 2014-06-30 | $32.76 10-Q · filed 2014-08-07 | |||
| 2014-03-31 | $30.42 10-Q · filed 2014-05-09 | |||
| 2013-12-31 | $13.59 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |